Who
Amit Munshi
Director
Company insider
Files Form 4 as: Director, Inhibikase Therapeutics; Director, Zura Bio; Director, Arcutis Biotherapeutics; Director, Damora Therapeutics; President and CEO, Arena Pharmaceuticals; Director, Pulmatrix; Chief Executive Officer, EPIRUS Biopharmaceuticals.
In numbers
- Trades disclosed
- 140
- Buys
- 13
- Sells
- 12
- Bought
- $2.0M
- Sold
- $29.2M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 15 Jul 2014
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 21 Feb 2026filed 24 Feb 2026 | IKT Inhibikase TherapeuticsBiotechnology | SEC FORM 4 Code D | —19,089 at $0.00 | filing |
| 21 Feb 2026filed 24 Feb 2026 | IKT Inhibikase TherapeuticsBiotechnology | SEC FORM 4 Code D | —19,089 at $0.00 | filing |
| 4 Dec 2025filed 8 Dec 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,502 at $0.00 | filing |
| 4 Dec 2025filed 8 Dec 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,177 at $0.00 | filing |
| 4 Dec 2025filed 8 Dec 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —2,021 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,176 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —720 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 21 Feb 2025filed 28 Aug 2025 | IKT Inhibikase TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,265 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,600 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | IKT Inhibikase Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —116,585 at $0.00 | filing |
| 9 Dec 2024filed 11 Dec 2024 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —117,000 at $0.00 | filing |
News
Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)IKT · themarketsdaily.com · 10 Oct 2026Zura Bio Limited (NASDAQ:ZURA) Stock Has Average Price Target of $17.00ZURA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Amit Munshi; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.